NEU 2.37% $19.39 neuren pharmaceuticals limited

Neuren Media and Analyst Coverage, page-1138

  1. 1,175 Posts.
    lightbulb Created with Sketch. 304

    I actually believe in the analyst's claim regarding NEU's desire to conduct all phase 3 trials. They certainty have no problem going alone given they have the capability/funding unless any interest party put forward a 'fair' offer.
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.